Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeTech ScientificLFTSF 95 Equity-to-Asset is 0.70 as of Dec. 2025, which is 7% below its 10-year median of 0.75. GuruFocus rates LFTSF with a GF Score™ of 95/100 and a GF Value™ of $0.37. The stock has 4 warning signs investors should review. Among 851 Medical Devices & Instruments companies, LifeTech Scientific ranks better than 60.28% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. LifeTech Scientific's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $498.7 Mil. LifeTech Scientific's Total Assets for the quarter that ended in Dec. 2025 was $711.7 Mil.
Therefore, LifeTech Scientific's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.70.
The historical rank and industry rank for LifeTech Scientific's Equity-to-Asset or its related term are showing as below:
LFTSF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.65 Med: 0.75 Max: 0.83
Current: 0.7
During the past 13 years, the highest Equity to Asset Ratio of LifeTech Scientific was 0.83. The lowest was 0.65. And the median was 0.75.
LFTSF's Equity-to-Asset is ranked better than 60.28% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs LFTSF: 0.70
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
LifeTech Scientific Equity-to-Asset Related Terms
LifeTech Scientific Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFTSF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, LifeTech Scientific's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
LifeTech Scientific's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific (LFTSF) has a Equity-to-Asset of 0.70 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on LifeTech Scientific and its competitors. This is near median its historical median of 0.75. Over the past decade, LifeTech Scientific's Equity-to-Asset has ranged from 0.65 to 0.83. According to the industry distribution chart, LifeTech Scientific ranks #338 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 39.7%.
Is LifeTech Scientific's Equity-to-Asset too high?
LifeTech Scientific's current Equity-to-Asset of 0.70 is near median its 10-year median of 0.75. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 0.83. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. LifeTech Scientific's value of 0.70 is 9.4% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #338 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #338 out of 851 companies for Equity-to-Asset. This puts LifeTech Scientific in the upper half of its industry. The industry median Equity-to-Asset is 0.64. LifeTech Scientific's value of 0.70 is 9.4% above this benchmark. Historically, LifeTech Scientific's own Equity-to-Asset has ranged from 0.65 to 0.83 over the past decade. While the company's 10-year median is 0.75 vs. the industry median of 0.64, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current Equity-to-Asset of 0.70 is 9.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current Equity-to-Asset is 0.70, which is near median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (LFTSF) has a current Equity-to-Asset of 0.70. The stock's GF Value™ is $0.37, compared to a current price of $0.23 — trading 36.9% below its estimated fair value. The current Equity-to-Asset is 0.70, which is near median its 10-year median of 0.75 and 9.4% above the Medical Devices & Instruments industry median of 0.64. LifeTech Scientific's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For LifeTech Scientific (LFTSF), the current Equity-to-Asset is 0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (LFTSF) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of $0.23 is trading 36.9% below its estimated GF Value™ of $0.37.
Key valuation signals for LFTSF:
Equity-to-Asset: 0.70 (near median its 10-year median of 0.75)
GF Value™: $0.37 vs. price of $0.23 (36.9% below fair value)
Industry Position: 9.4% above the Medical Devices & Instruments median (#338 of 851)
No single metric tells the full story. See the LFTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score
Get the complete analysis for LFTSF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFTSF has been successfully added to your 
